期刊
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
卷 37, 期 4, 页码 923-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2008.08.004
关键词
Sympathomimetic drugs; Lipase inhibitor; Cannabinoid receptor antagonists; Glucagon-like peptide analogues
Only two drugs are currently approved for long-term use in the treatment of obesity and four others for short-term use. Evaluating the risk-benefit profile is an essential first step. For individuals who have a low body mass index for whom the risk is small, the risk profile must make the drug acceptable for almost everyone. For higher-risk patients, such as those planning intestinal bypass or who have sleep apnea, a wider range of drugs may be considered. Obesity is a chronic disease that has many causes. Treatment is aimed at palliation-that is, producing and maintaining weight loss. Regardless of the primary site of action, the net effect must be a reduction in food intake or increase in energy expenditure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据